{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for prednisolone root_notes_note in Note (approximate match)
Status:
Possibly Marketed Outside US
Source:
ANDA077154
(1968)
Source URL:
First approved in 1968
Source:
ANDA077154
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
21 CFR 338
(2017)
Source URL:
First approved in 1955
Source:
NDA202100
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
ANDA091135
(2012)
Source URL:
First approved in 1948
Source:
NDA018279
Source URL:
Class:
POLYMER
Status:
US Approved OTC
Source:
21 CFR 346.18(b) anorectal:astringent witch hazel (haramelis water)
Source URL:
First marketed in 1921
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03371381: Phase 1/Phase 2 Interventional Terminated Adenocarcinoma of Lung
(2018)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
G1 SPECIFIED SUBSTANCE
Status:
Other
Class:
G1 SPECIFIED SUBSTANCE
Status:
Other
Class:
G1 SPECIFIED SUBSTANCE
Status:
Possibly Marketed Outside US
Source:
JBA Collagen-B by Advanced Pharmaceutical Services, Inc. Dba Affordable Quality Pharmaceuticals
(2021)
Source URL:
First approved in 2021
Source:
JBA Collagen-B by Advanced Pharmaceutical Services, Inc. Dba Affordable Quality Pharmaceuticals
Source URL:
Class:
G1 SPECIFIED SUBSTANCE
Status:
US Approved Rx
(2023)
Source:
NDA217159
(2023)
Source URL:
First approved in 2023
Source:
NDA217159
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
BioLineRx Ltd has developed BL-8040, a short peptide for the treatment of solid tumors, acute myeloid leukemia, or AML, and stem-cell mobilization for bone-marrow transplantation. BL-8040 acts as CXCR4 antagonist. CXCR4 is a chemokine receptor that is directly involved in tumor progression, angiogenesis, metastasis, and cell survival. In February 2019 US Food and Drug Administration (FDA) has granted Orphan Drug Designation to BL-8040, for the treatment of pancreatic cancer. Previously FDA had granted Orphan Drug Designation for the treatment of acute myeloid leukemia and stem-cell mobilization.
